Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26452946 | 1.00 | GBA1 (0.44) | GBA1CCR5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12414623 | 0.82 | — | — | |
| SCHEMBL25744992 | 0.82 | — | — | |
| SCHEMBL18309930 | 0.82 | — | — | |
| SCHEMBL14626990 | 0.82 | — | — | |
| SCHEMBL19122720 | 0.82 | — | — | |
| SCHEMBL804927 | 0.82 | — | — | |
| SCHEMBL24213029 | 0.80 | — | — | |
| SCHEMBL21725556 | 0.80 | — | — | |
| SCHEMBL17037474 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230183489-A1 | COLORING COMPOSITION, INK JET RECORDING METHOD, IMAGE RECORDED MATERIAL, AND COLORING AGENT COMPOUND | FUJIFILM CORPORATION (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230002404-A1 | HETEROBICYCLIC CARBOXAMIDES AND USES THEREOF | ALCON INC. (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-3679039-B1 | TYROSINE ANALOGUES DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011871-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20210015948-A1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | THE GENERAL HOSPITAL CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8648037-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015948-A1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | MPI, MAG, MNS1 | GBA1 881/4885CCR5 3198/4885CHRNB2 1921/4885 |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | PREP, PRSS1, PEPD | GBA1 710/4885CCR5 634/4885CHRNB2 4885/4885 |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | GBA1 1745/4885CCR5 4212/4885CHRNB2 4089/4885 |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | GBA1 412/4885CCR5 167/4885CHRNB2 4850/4885 |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MAP3K19, MAP3K15, MAP3K12 | GBA1 1783/4885CCR5 4028/4885CHRNB2 4202/4885 |
| US-20230002404-A1 | HETEROBICYCLIC CARBOXAMIDES AND USES THEREOF | UACA, PHKG2, CCAR2 | GBA1 955/4885CCR5 1824/4885CHRNB2 3239/4885 |
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | GBA1 2928/4885CCR5 3769/4885CHRNB2 4838/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GBA1 2928/4885CCR5 3769/4885CHRNB2 4838/4885 |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | GBA1 710/4885CCR5 634/4885CHRNB2 4885/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | GBA1 388/4885CCR5 241/4885CHRNB2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.